字号·· | 护眼
CNBC

诺和诺德:试验显示Wegovy注射剂降低儿童BMI和肥胖率Novo says Wegovy injection lowers BMI and obesity rates in children in trial

点「原文对照」整页切到原文,或双击某段只看那段的原文。

诺和诺德公布了一项晚期临床试验的完整结果,显示Wegovy(司美格鲁肽)帮助6岁至12岁以下患有肥胖症的儿童显著降低了体重指数(BMI)。

Novo released full results from a late-stage trial showing Wegovy helped children ages 6 to under 12 with obesity significantly lower their body mass index.

Wegovy已获批用于治疗12岁及以上儿童的肥胖症,但目前尚无获批药物可用于12岁以下儿童。

Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.

该药企表示,在孩子们身上未观察到与生长或青春期发育相关的安全性问题。

The drugmaker said it observed no safety concerns related to growth or pubertal development in the kids.

与安慰剂相比,Wegovy在68周时使BMI平均降低了约19.7个百分点,接受药物治疗的儿童BMI下降了17.4%,而接受安慰剂的儿童BMI上升了2.2%。这些结果假设患者在试验期间持续接受治疗。

Novo Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, with BMI falling 17.4% among children receiving the drug and rising 2.2% among those receiving a placebo. Those results assumed patients stayed on treatment during the trial.

在评估研究中的所有儿童(包括中途停止治疗者)时,Wegovy在68周时使BMI平均比安慰剂降低了约16.2个百分点。研究中所有167名儿童在整个试验期间均接受了生活方式干预,包括低热量饮食和增加体育活动。

When evaluating all children in the study, including those who discontinued treatment, Wegovy lowered BMI by an estimated average of 16.2 percentage points more than the placebo at 68 weeks. All 167 kids in the study received lifestyle modifications throughout the trial, including a reduced-calorie diet and increased physical activity.

这些详细结果标志着治疗儿童肥胖症迈出了令人鼓舞的一步——这是一种慢性疾病,可导致严重的心血管、代谢和心理社会后果,但针对年幼儿童的治疗选择一直很少。如果不加干预,儿童肥胖症可能延续至成年,带来更早、更严重的健康并发症。

The detailed results mark an encouraging step forward in treating childhood obesity — a chronic disease that can carry serious cardiovascular, metabolic and psychosocial consequences but has had few treatment options for younger children. When left unaddressed, childhood obesity can extend into adulthood, bringing earlier and more severe health complications.

诺和诺德肥胖症医学总监Andrea Traina博士表示:“这是这一非常年轻患者群体中非常沉重的疾病负担。”

"This is a very significant disease burden in this very young patient population," said Dr. Andrea Traina, Novo's medical director lead of obesity.

根据世界肥胖联合会的数据,2025年,全球约有1.77亿名5至19岁的儿童和青少年受肥胖症影响。预计到2040年,这一数字将上升至2.28亿。

In 2025, the disease affected an estimated roughly 177 million children and teens ages 5 to 19 worldwide, according to the World Obesity Federation. That figure is projected to rise to 228 million by 2040.

虽然Wegovy已获批用于治疗12岁及以上儿童的肥胖症,但目前尚无获批药物用于12岁以下儿童。最新结果提供了证据,表明Wegovy有望填补这一治疗空白,能安全有效地降低年仅6岁儿童的病情严重程度。

While Wegovy is already approved to treat obesity in children ages 12 and older, there are currently no approved medications for those under 12. The latest results offer evidence that Wegovy can potentially fill that treatment gap, safely and effectively reducing the severity of the disease in children as young as 6.

在诺和诺德的试验中,85%的儿童入组时患有中度至重度肥胖,分别对应体重指数(BMI)阈值35及以上和40及以上。近一半儿童已至少患有一种肥胖相关并发症,如高血压、高胆固醇或睡眠呼吸暂停。

In Novo's trial, 85% of children started with moderate to severe obesity, which corresponds to BMI thresholds of 35 and above and 40 or higher, respectively. Nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea.

但试验显示,接受Wegovy治疗的儿童中,超过40%在试验进行68周后不再被归类为肥胖,前提是患者持续用药。诺和诺德于9月首次公布了这一结果。

But more than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks of the trial, assuming patients stayed on treatment. Novo initially shared that result in September.

特雷纳表示:“我们正致力于在这一患群年纪尚小、且因发病早而面临更严重和加速病情进展的高风险时,实现对这一慢性病的控制。”

"We are driving towards control of this chronic disease in that patient population when they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early," Traina said.

诺和诺德表示,Wegovy在儿童中的总体安全性和耐受性——即患者对药物的适应情况——与成人试验中观察到的情况一致。公司补充称,未观察到与儿童生长发育或青春期发育相关的安全性问题。

Novo said Wegovy's overall safety and tolerability among children — how well patients managed the drug — were consistent with those seen in trials with adults. The company added that it observed no safety concerns related to growth or pubertal development in the kids.

不过,特雷纳表示,这项为期两年的研究并未确定更早治疗肥胖是否能改变其长期病程,也未明确儿童成长为成人后治疗和维持治疗可能是什么样子。她说:“这仍是一个证据空白”,并指出了未来研究的潜力。

Still, the two-year study does not establish whether treating obesity earlier can change its long-term trajectory, or what treatment and maintenance might look like as children grow into adulthood, Traina said. "That is something that is still an evidence gap," she said, pointing to the potential of future research.

阅读媒体原文 ↗